Trials / Terminated
TerminatedNCT02900690
Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this project is to assess the average cost of the treatment of bleeding postpartum with recombinant activated factor VII (NovoSeven®) and compare it to the reference strategy. Costs related to medicine NovoSeven® can generate surplus, but it also avoids in some cases very costly invasive procedures. It will be interesting to compare the average cost of the complete strategies supported.
Conditions
Timeline
- Start date
- 2010-04-22
- Primary completion
- 2010-11-05
- Completion
- 2010-11-05
- First posted
- 2016-09-14
- Last updated
- 2018-03-26
Source: ClinicalTrials.gov record NCT02900690. Inclusion in this directory is not an endorsement.